Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In April 2007, Australia became the first country to introduce a national government-funded human papillomavirus (HPV) vaccination program. We evaluated the program's impact on genotype-specific HPV infection prevalence through a repeat survey of women attending clinical services. METHODS: HPV genoprevalence in women aged 18-24 years attending family planning clinics in the prevaccine period (2005-2007) was compared with prevalence among women of the same age group in the postvaccine period (2010-2011). The same recruitment and testing strategies were utilized for both sets of samples, and comparisons were adjusted for potentially confounding variables. RESULTS: The prevalence of vaccine HPV genotypes (6, 11, 16, and 18) was significantly lower in the postvaccine sample than in the prevaccine sample (6.7% vs 28.7%; P < .001), with lower prevalence observed in both vaccinated and unvaccinated women compared with the prevaccine population (5.0% [adjusted odds ratio, 0.11; 95% confidence interval, 0.06-0.21] and 15.8% [adjusted odds ratio, 0.42; 95% confidence interval, 0.19-0.93], respectively). A slightly lower prevalence of nonvaccine oncogenic HPV genotypes was also found in vaccinated women (30.8% vs 37.6%; adjusted odds ratio, 0.68; 95% confidence interval, 0.46-0.99). CONCLUSIONS: Four years after the commencement of the Australian HPV vaccination program, a substantial decrease in vaccine-targeted genotypes is evident and should, in time, translate into reductions in HPV-related lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886 · cited 1×
“16 and 18 [3], the main causes of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) in Australian women, and genotypes 6 and 11, which cause most genital warts [4, 5].”
BackgroundSelf-citationImproved Amplification of Genital Human Papillomaviruses
Gravitt, P. E., Peyton, C. L., Alessi, T. Q., Wheeler, C. M., Coutlée, F., Hildesheim, A., Schiffman, M. H., Scott, D. R., & Apple, R. J. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.1.357-361.2000 · Cited by 1,137 · cited 1×
“Any specimen shown to be negative for HR-HPV types was tested for the presence of mucosal HPV DNA using L1 consensus primer set PGMY09PGMY11 [15].”
MethodBrotherton, J. M., Fridman, M., May, C. L., Chappell, G., Saville, A. M., & Gertig, D. M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60551-5 · Cited by 598
Self-citationGarland, S. M., Steben, M., Sings, H. L., James, M., Lu, S., Railkar, R., Barr, E., Haupt, R. M., & Joura, E. A. (2009) · The Journal of Infectious Diseases · doi:10.1086/597071 · Cited by 532
Self-citationDonovan, B., Franklin, N., Guy, R., Grulich, A. E., Regan, D. G., Ali, H., Wand, H., & Fairley, C. K. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70225-5 · Cited by 380
Read, T. R. H., Hocking, J. S., Chen, M. Y., Donovan, B., Bradshaw, C. S., & Fairley, C. K. (2011) · Sexually Transmitted Infections · doi:10.1136/sextrans-2011-050234 · Cited by 249
Efficacy and other milestones for human papillomavirus vaccine introduction
Pagliusi, S. R., & Aguado, M. T. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.046 · Cited by 216
Human Papillomavirus Vaccine and Sexual Behavior Among Adolescent and Young Women
Liddon, N. C., Leichliter, J. S., & Markowitz, L. E. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.09.024 · Cited by 171
Rissel, C. E., Richters, J., Grulich, A. E., de Visser, R. O., & Smith, A. M. A. (2003) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2003.tb00800.x · Cited by 134
Gertig, D. M., Brotherton, J. M. L., & Saville, M. (2011) · Sexual Health · doi:10.1071/sh10001 · Cited by 116
Self-citationthe WHINURS study group, Garland, S. M., Brotherton, J. M., Condon, J. R., McIntyre, P. B., Stevens, M. P., Smith, D. W., & Tabrizi, S. N. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-104 · Cited by 80
Self-citationBrotherton, J. M. L., Gertig, D. M., Chappell, G., Rowlands, L., & Saville, M. (2011) · Communicable Diseases Intelligence · doi:10.33321/cdi.2011.35.18 · Cited by 57
Self-citationStevens, M. P., Rudland, E., Garland, S. M., & Tabrizi, S. N. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.02608-05 · Cited by 55
Self-citationStevens, M. P., Garland, S. M., & Tabrizi, S. N. (2008) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.09.018 · Cited by 52
Self-citationBrotherton, J. M. L., Kaldor, J. M., & Garland, S. M. (2010) · Sexual Health · doi:10.1071/sh09137 · Cited by 48
Self-citationWong, C. A., Saraiya, M., Hariri, S., Eckert, L. O., Howlett, R. I., Markowitz, L. E., Brotherton, J. M. L., Sinka, K., Martínez-Montañez, O. G., Kjær, S. K., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.018 · Cited by 43
Self-citationHuman papillomavirus genotyping using a modified linear array detection protocol
Stevens, M. P., Garland, S. M., & Tabrizi, S. N. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.02.007 · Cited by 39
Self-citationSmith, A., Agius, P. A., & Mitchell, A. (2009) · Analysis & Policy Observatory · doi:10.4225/50/557e5bef5b34b · Cited by 37
Stevens, M. P., Garland, S. M., & Tabrizi, S. N. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01169-08 · Cited by 34
Self-citationCervical adenoid basal carcinoma, five cases and literature review
Layton-Henry, J., Scurry, J., Planner, R. S., Allen, D. G., Sykes, P. H., Garland, S. M., Borg, Å., & Tabrizi, S. N. (1996) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1996.06030193.x · Cited by 33
Self-citationEvaluation of a Modified Reverse Line Blot Assay for Detection and Typing of Human Papillomavirus
Tabrizi, S. N., Stevens, M. P., Chen, S., Rudland, E., Kornegay, J. R., & Garland, S. M. (2005) · American Journal of Clinical Pathology · doi:10.1309/mpernj0g62rechcq · Cited by 31
Self-citation
Cited by
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Self-citationDrolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., Baldo, V., Brassard, P., Brotherton, J. M. L., Callander, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30298-3 · Cited by 1,384
Self-citationDrolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Self-citationArbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit192 · Cited by 521
Metadata
- Authors
- Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-19
- Volume
- 206
- Issue
- 11
- Pages
- 1645-1651
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2129827681
- Cited by
- 264
- References
- 22
- FWCI
- 26.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.